Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging

Alexandra M V Wennberg, Deborah Gustafson, Clinton E. Hagen, Rosebud O Roberts, David S Knopman, Clifford R Jr. Jack, Ronald Carl Petersen, Michelle M Mielke, Gene Bowman

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Adiponectin, a protein involved in inflammatory pathways, may impact the development and progression of Alzheimer's disease (AD). Adiponectin levels have been associated with mild cognitive impairment (MCI) and AD; however, its association with Alzheimer-associated neuroimaging and cognitive outcomes is unknown. Objective: Determine the cross-sectional association between plasma adiponectin and neuroimaging and cognitive outcomes in an older population-based sample. Methods: Multivariable adjusted regression models were used to investigate the association between plasma adiponectin and hippocampal volume (HVa), PiB-PET, FDG PET, cortical thickness, MCI diagnosis, and neuropsychological test performance. Analyses included 535 non-demented participants aged 70 and older enrolled in the Mayo Clinic Study of Aging. Results: Women had higher adiponectin than men (12,631ng/mL versus 8,908ng/mL, p<0.001). Among women, higher adiponectin was associated with smaller HVa (B=-0.595; 95 CI -1.19, -0.005), poorer performance in language (B=-0.676; 95 CI -1.23, -0.121), and global cognition (B=-0.459; 95 CI -0.915, -0.002), and greater odds of a MCI diagnosis (OR=6.23; 95 CI 1.20, 32.43). In analyses stratified by sex and elevated amyloid (PiB-PET SUVR >1.4), among women with elevated amyloid, higher adiponectin was associated with smaller HVa (B=-0.723; 95 CI -1.43, -0.014), poorer performance in memory (B=-1.02; 95 CI -1.73, -0.312), language (B=-0.896; 95 CI -1.58, -0.212), global cognition (B=-0.650; 95 CI -1.18, -0.116), and greater odds of MCI (OR=19.34; 95 CI 2.72, 137.34). Conclusion: Higher plasma adiponectin was associated with neuroimaging and cognitive outcomes among women. Longitudinal analyses are necessary to determine whether higher adiponectin predicts neurodegeneration and cognitive decline.

Original languageEnglish (US)
Pages (from-to)573-581
Number of pages9
JournalJournal of Alzheimer's Disease
Volume53
Issue number2
DOIs
StatePublished - 2016

Fingerprint

Adiponectin
Neuroimaging
Cognition
Serum
Alzheimer Disease
Neuropsychological Tests
Amyloid
Language
Cognitive Dysfunction
Population

Keywords

  • Adiponectin
  • Amyloid-PET
  • Cognition
  • FDG-PET
  • Hippocampal volume
  • Mild cognitive impairment

ASJC Scopus subject areas

  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging. / Wennberg, Alexandra M V; Gustafson, Deborah; Hagen, Clinton E.; Roberts, Rosebud O; Knopman, David S; Jack, Clifford R Jr.; Petersen, Ronald Carl; Mielke, Michelle M; Bowman, Gene.

In: Journal of Alzheimer's Disease, Vol. 53, No. 2, 2016, p. 573-581.

Research output: Contribution to journalArticle

Wennberg, Alexandra M V ; Gustafson, Deborah ; Hagen, Clinton E. ; Roberts, Rosebud O ; Knopman, David S ; Jack, Clifford R Jr. ; Petersen, Ronald Carl ; Mielke, Michelle M ; Bowman, Gene. / Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging. In: Journal of Alzheimer's Disease. 2016 ; Vol. 53, No. 2. pp. 573-581.
@article{fd1194c52d3b48b5a749f8e80078c58f,
title = "Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging",
abstract = "Background: Adiponectin, a protein involved in inflammatory pathways, may impact the development and progression of Alzheimer's disease (AD). Adiponectin levels have been associated with mild cognitive impairment (MCI) and AD; however, its association with Alzheimer-associated neuroimaging and cognitive outcomes is unknown. Objective: Determine the cross-sectional association between plasma adiponectin and neuroimaging and cognitive outcomes in an older population-based sample. Methods: Multivariable adjusted regression models were used to investigate the association between plasma adiponectin and hippocampal volume (HVa), PiB-PET, FDG PET, cortical thickness, MCI diagnosis, and neuropsychological test performance. Analyses included 535 non-demented participants aged 70 and older enrolled in the Mayo Clinic Study of Aging. Results: Women had higher adiponectin than men (12,631ng/mL versus 8,908ng/mL, p<0.001). Among women, higher adiponectin was associated with smaller HVa (B=-0.595; 95 CI -1.19, -0.005), poorer performance in language (B=-0.676; 95 CI -1.23, -0.121), and global cognition (B=-0.459; 95 CI -0.915, -0.002), and greater odds of a MCI diagnosis (OR=6.23; 95 CI 1.20, 32.43). In analyses stratified by sex and elevated amyloid (PiB-PET SUVR >1.4), among women with elevated amyloid, higher adiponectin was associated with smaller HVa (B=-0.723; 95 CI -1.43, -0.014), poorer performance in memory (B=-1.02; 95 CI -1.73, -0.312), language (B=-0.896; 95 CI -1.58, -0.212), global cognition (B=-0.650; 95 CI -1.18, -0.116), and greater odds of MCI (OR=19.34; 95 CI 2.72, 137.34). Conclusion: Higher plasma adiponectin was associated with neuroimaging and cognitive outcomes among women. Longitudinal analyses are necessary to determine whether higher adiponectin predicts neurodegeneration and cognitive decline.",
keywords = "Adiponectin, Amyloid-PET, Cognition, FDG-PET, Hippocampal volume, Mild cognitive impairment",
author = "Wennberg, {Alexandra M V} and Deborah Gustafson and Hagen, {Clinton E.} and Roberts, {Rosebud O} and Knopman, {David S} and Jack, {Clifford R Jr.} and Petersen, {Ronald Carl} and Mielke, {Michelle M} and Gene Bowman",
year = "2016",
doi = "10.3233/JAD-151201",
language = "English (US)",
volume = "53",
pages = "573--581",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging

AU - Wennberg, Alexandra M V

AU - Gustafson, Deborah

AU - Hagen, Clinton E.

AU - Roberts, Rosebud O

AU - Knopman, David S

AU - Jack, Clifford R Jr.

AU - Petersen, Ronald Carl

AU - Mielke, Michelle M

AU - Bowman, Gene

PY - 2016

Y1 - 2016

N2 - Background: Adiponectin, a protein involved in inflammatory pathways, may impact the development and progression of Alzheimer's disease (AD). Adiponectin levels have been associated with mild cognitive impairment (MCI) and AD; however, its association with Alzheimer-associated neuroimaging and cognitive outcomes is unknown. Objective: Determine the cross-sectional association between plasma adiponectin and neuroimaging and cognitive outcomes in an older population-based sample. Methods: Multivariable adjusted regression models were used to investigate the association between plasma adiponectin and hippocampal volume (HVa), PiB-PET, FDG PET, cortical thickness, MCI diagnosis, and neuropsychological test performance. Analyses included 535 non-demented participants aged 70 and older enrolled in the Mayo Clinic Study of Aging. Results: Women had higher adiponectin than men (12,631ng/mL versus 8,908ng/mL, p<0.001). Among women, higher adiponectin was associated with smaller HVa (B=-0.595; 95 CI -1.19, -0.005), poorer performance in language (B=-0.676; 95 CI -1.23, -0.121), and global cognition (B=-0.459; 95 CI -0.915, -0.002), and greater odds of a MCI diagnosis (OR=6.23; 95 CI 1.20, 32.43). In analyses stratified by sex and elevated amyloid (PiB-PET SUVR >1.4), among women with elevated amyloid, higher adiponectin was associated with smaller HVa (B=-0.723; 95 CI -1.43, -0.014), poorer performance in memory (B=-1.02; 95 CI -1.73, -0.312), language (B=-0.896; 95 CI -1.58, -0.212), global cognition (B=-0.650; 95 CI -1.18, -0.116), and greater odds of MCI (OR=19.34; 95 CI 2.72, 137.34). Conclusion: Higher plasma adiponectin was associated with neuroimaging and cognitive outcomes among women. Longitudinal analyses are necessary to determine whether higher adiponectin predicts neurodegeneration and cognitive decline.

AB - Background: Adiponectin, a protein involved in inflammatory pathways, may impact the development and progression of Alzheimer's disease (AD). Adiponectin levels have been associated with mild cognitive impairment (MCI) and AD; however, its association with Alzheimer-associated neuroimaging and cognitive outcomes is unknown. Objective: Determine the cross-sectional association between plasma adiponectin and neuroimaging and cognitive outcomes in an older population-based sample. Methods: Multivariable adjusted regression models were used to investigate the association between plasma adiponectin and hippocampal volume (HVa), PiB-PET, FDG PET, cortical thickness, MCI diagnosis, and neuropsychological test performance. Analyses included 535 non-demented participants aged 70 and older enrolled in the Mayo Clinic Study of Aging. Results: Women had higher adiponectin than men (12,631ng/mL versus 8,908ng/mL, p<0.001). Among women, higher adiponectin was associated with smaller HVa (B=-0.595; 95 CI -1.19, -0.005), poorer performance in language (B=-0.676; 95 CI -1.23, -0.121), and global cognition (B=-0.459; 95 CI -0.915, -0.002), and greater odds of a MCI diagnosis (OR=6.23; 95 CI 1.20, 32.43). In analyses stratified by sex and elevated amyloid (PiB-PET SUVR >1.4), among women with elevated amyloid, higher adiponectin was associated with smaller HVa (B=-0.723; 95 CI -1.43, -0.014), poorer performance in memory (B=-1.02; 95 CI -1.73, -0.312), language (B=-0.896; 95 CI -1.58, -0.212), global cognition (B=-0.650; 95 CI -1.18, -0.116), and greater odds of MCI (OR=19.34; 95 CI 2.72, 137.34). Conclusion: Higher plasma adiponectin was associated with neuroimaging and cognitive outcomes among women. Longitudinal analyses are necessary to determine whether higher adiponectin predicts neurodegeneration and cognitive decline.

KW - Adiponectin

KW - Amyloid-PET

KW - Cognition

KW - FDG-PET

KW - Hippocampal volume

KW - Mild cognitive impairment

UR - http://www.scopus.com/inward/record.url?scp=84979239899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979239899&partnerID=8YFLogxK

U2 - 10.3233/JAD-151201

DO - 10.3233/JAD-151201

M3 - Article

C2 - 27163809

AN - SCOPUS:84979239899

VL - 53

SP - 573

EP - 581

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -